AFNT-212 / Affini-T Therap - LARVOL DELTA

Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (Businesswire) - "Affini-T Therapeutics, Inc...today announced that a Trial-In-Progress poster for the Company’s Phase 1 clinical trial evaluating AFNT-211 targeting KRAS G12V will be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting held in Houston, TX, November 6-10. The team will present three additional posters with preclinical data from its non-viral TRAC-knocked-in T cell therapy targeting TP53-R175H and bi-specific T cell engager programs targeting TP53-R175H, KRAS G12D and KRAS G12V."

P1 data • Preclinical • Oncology • Solid Tumor

Affini-T Therapeutics to Present Data From Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27^th Annual Meeting (Businesswire) - "Affini-T Therapeutics, Inc...today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11....'We look forward to presenting new data showing that THRIVETM-engineered A11 KRAS G12D-targeting TCR T cells (AFNT-212) and TP53 R175H-targeting TCR T cells demonstrated superior cytotoxicity against tumor cells relative to LVV-engineered cells both in vitro and in vivo, at ASGCT this year.'"

Preclinical • Oncology • Solid Tumor

AFNT-212: A TRAC-knocked-in KRASG12D-specific TCR-T cell product enhanced with CD8αβ and a chimeric cytokine receptor for treatment of solid cancers (AACR 2024) - "The manufacturing of AFNT-212 consistently delivered >50-fold expansion of engineered TCR-T cells to meet expected clinical dose levels and exhibit memory/stemness phenotypes and negligible markers of immunologic exhaustion.AFNT-212, a novel TCR T cell therapy targeting KRASG12D mutant tumors, demonstrates robust activity against KRASG12D mutant tumors in vitro and in vivo. The robust manufacturing process developed using non-viral gene editing in the TRAC locus will support future clinical development of AFNT-212."

Oncology • Solid Tumor • CD4 • CD8 • HLA-A • KRAS

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Businesswire) - "AFNT-212-engineered TCR-T cells showed high functional avidity and in vitro cytotoxicity against KRAS G12D-positive tumor cell lines, including CL40 (colon), PANC-1 and HPAF-II (pancreas), SK-LU-1 (lung), HuCCT1 (cholangiocarcinoma), etc. Additionally, engineered TCR-T cells demonstrated robust and durable anti-tumor activity in vivo and low risk of off-target/off-tumor toxicity. Affini-T’s proprietary non-viral knock-in (KI) THRIVE™ platform achieved high transgene integration efficiency and cell growth to yield relevant numbers of engineered TCR-T cells for clinical application. The study supports the planned clinical investigation of the novel KRAS G12D mutant TCR-engineered CD4+ and CD8+ T cell therapy in 2024."

New trial • Preclinical • Cholangiocarcinoma • Colon Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting (Businesswire) - "Affini-T Therapeutics, Inc...announced that preclinical data from its oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held in San Diego, CA. In addition, two trial-in-progress posters for Affini-T's Phase 1 clinical-stage programs targeting KRAS G12V, the company-sponsored AFNT-211 study and the Fred Hutchinson Cancer Center investigator-initiated AFNT-111 study, will be presented at the same conference."

Trial status • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Non-viral targeted knock-in of a KRAS G12D specific TCR, CD8αβ, and chimeric cytokine receptor in the TRAC locus outperforms lentiviral-based engineering of T cells (SITC 2023) - "Conclusions Non-viral targeted KI engineered AFNT-212 cells drive a robust coordinated CD4/CD8 T cell response against KRAS G12D-harboring tumors and outperform LVV-engineered cells. Our work supports the planned clinical development of this novel TCR-engineered T cell therapy for treating KRAS-mutant solid tumors."

IO biomarker • Oncology • Solid Tumor • CD4 • CD8 • HLA-A • KRAS

Directing a high avidity KRAS G12D-specific TCR engineered with a CD8αβ co-receptor and chimeric cytokine receptor using non-viral knock-in enhances anti-tumor responses (SITC 2023) - "Conclusions We report a novel TCR gene therapy approach targeting mutant KRAS G12D-expressing tumors with a coordinated CD4/CD8 T cell response that has a promising efficacy and safety profile. Our work supports the planned clinical development of AFNT-212 as a novel non-viral KI TCR-engineered T cell therapy for KRAS-mutant solid tumors."

IO biomarker • Oncology • Solid Tumor • CD4 • CD8 • HLA-A • KRAS • TRB

Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (Businesswire) - "Affini-T Therapeutics, Inc...today announced that preclinical data from its oncogenic driver program targeting KRAS G12D, AFNT-212, will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting....'Our data show that non-viral targeted knock-in engineered AFNT-212 T cells drive a robust coordinated CD4+ CD8+ T cell immune response against KRAS G12D mutated tumors with promising preclinical activity and tolerability, supporting the planned clinical development of our AFNT-212 T Cell Receptor-engineered therapy.'"

Preclinical • Oncology • Solid Tumor

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Businesswire) - "Affini-T Therapeutics, Inc...today announced that Loïc Vincent, Ph.D., Chief Scientific Officer and Christopher A. Klebanoff, M.D., physician-scientist at Memorial Sloan Kettering Cancer Center (MSK), who also serves as Scientific Co-founder and Advisor, Affini-T Therapeutics, are presenting data from the company’s T cell receptor (TCR) T cell therapy program targeting KRAS G12D mutations, at this year’s American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando."

Preclinical • Oncology • Solid Tumor

Affini-T Therapeutics to Present Novel CRISPR Gene Editing Data from its Oncogenic Driver Program Targeting KRAS at the American Society of Gene and Cell Therapy 26th Annual Meeting (Businesswire) - "Affini-T Therapeutics, Inc...announced that preclinical data for its oncogenic driver program targeting KRAS G12D, AFNT–212, will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, California....'We look forward to presenting encouraging preclinical data for our gene-edited KRAS G12D-targeting TCR-T cell therapy, AFNT-212, at ASGCT this year'."

Preclinical • Oncology • Solid Tumor